ARCT Arcturus Therapeutics Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARCT

Price (delayed)

$15.12

Market cap

$400.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.56

Enterprise value

$253.85M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
Arcturus Therapeutics Holdings's gross profit has increased by 27% QoQ
The revenue has grown by 27% since the previous quarter
Arcturus Therapeutics Holdings's debt has surged by 92% YoY but it has decreased by 4.2% QoQ
ARCT's quick ratio is down by 10% year-on-year but it is up by 2.6% since the previous quarter
ARCT's equity is down by 44% year-on-year and by 15% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://arcturusrx.com
Peers: NRC NWBO

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.49M
Market cap
$400.57M
Enterprise value
$253.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.76
Price to sales (P/S)
7.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.93
Earnings
Revenue
$51.5M
EBIT
-$144.69M
EBITDA
-$143.41M
Free cash flow
-$175.8M
Per share
EPS
-$5.56
Free cash flow per share
-$6.64
Book value per share
$5.48
Revenue per share
$1.95
TBVPS
$11.09
Balance sheet
Total assets
$293.63M
Total liabilities
$147.96M
Debt
$90.96M
Equity
$145.67M
Working capital
$170.83M
Liquidity
Debt to equity
0.62
Current ratio
3.25
Quick ratio
3.16
Net debt/EBITDA
1.02
Margins
EBITDA margin
-278.5%
Gross margin
100%
Net margin
-284.8%
Operating margin
-285.3%
Efficiency
Return on assets
-43%
Return on equity
-80.4%
Return on invested capital
-580.1%
Return on capital employed
-66.4%
Return on sales
-281%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
2.72%
1 week
-4.79%
1 month
-12.8%
1 year
-44.78%
YTD
-10.85%
QTD
-10.85%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$51.5M
Gross profit
$51.5M
Operating income
-$146.92M
Net income
-$146.66M
Gross margin
100%
Net margin
-284.8%
Arcturus Therapeutics Holdings's net margin has surged by 87% YoY and by 30% QoQ
Arcturus Therapeutics Holdings's operating margin has surged by 87% YoY and by 29% QoQ
Arcturus Therapeutics Holdings's gross profit has increased by 27% QoQ
The revenue has grown by 27% since the previous quarter

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
2.76
P/S
7.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.93
The company's EPS rose by 27% YoY and by 11% QoQ
ARCT's P/B is 48% lower than its 5-year quarterly average of 5.2 and 18% lower than its last 4 quarters average of 3.3
ARCT's equity is down by 44% year-on-year and by 15% since the previous quarter
ARCT's price to sales (P/S) is 85% lower than its 5-year quarterly average of 50.4 and 79% lower than its last 4 quarters average of 35.7
The revenue has grown by 27% since the previous quarter

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has surged by 87% YoY and by 30% QoQ
The company's return on equity fell by 35% YoY and by 2.4% QoQ
The ROA has increased by 2.1% QoQ

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets is 98% higher than its total liabilities
Arcturus Therapeutics Holdings's total assets has decreased by 32% YoY and by 13% QoQ
Arcturus Therapeutics Holdings's total liabilities has decreased by 16% YoY and by 11% QoQ
Arcturus Therapeutics Holdings's debt is 38% lower than its equity
Arcturus Therapeutics Holdings's debt has surged by 92% YoY but it has decreased by 4.2% QoQ
ARCT's equity is down by 44% year-on-year and by 15% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.